Diagnostics For All

Diagnostics For All. It is a non-profit organization dedicated to developing ultra-low-cost, paper-based diagnostic devices designed for use in low-resource settings. Founded by Harvard University chemist George M. Whitesides and engineer Patrick S. Doyle, the organization leverages innovative microfluidics and biochemistry to create portable tests. Its mission is to address critical health and agricultural challenges in the developing world by providing accessible diagnostic tools that require no electricity or complex equipment.

● History and founding

The organization originated from pioneering research in the Whitesides Research Group at Harvard University in the mid-2000s, where the foundational technology for paper-based microfluidic devices was developed. It was formally established as a 501(c)(3) non-profit in 2007 by George M. Whitesides, a renowned chemist, and Patrick S. Doyle, then a postdoctoral fellow. The concept gained significant early support after winning the inaugural Saving Lives at Birth grant competition in 2011, a partnership between the United States Agency for International Development, the Bill & Melinda Gates Foundation, and Grand Challenges Canada. This validation helped transition the technology from academic labs at the Wyss Institute for Biologically Inspired Engineering into a dedicated entity focused on real-world deployment.

● Technology and innovation

The core innovation of Diagnostics For All is its platform of paper-based analytical devices, which function similarly to litmus paper but are patterned with hydrophobic barriers to create precise channels and test zones. These devices utilize principles of capillary action to move small volumes of biological samples, such as blood or urine, through pre-treated zones containing specific chemical reagents. This enables the detection of biomarkers for conditions like liver function, pre-eclampsia, and HIV treatment monitoring. The tests are designed to be read visually, often by a color change, eliminating the need for expensive readers, stable electricity, or highly trained personnel, making them ideal for use in remote clinics or field settings.

● Applications and impact

The organization's tests have been deployed in multiple countries to address both human health and agricultural needs. Key health applications include monitoring liver toxicity in patients receiving antiretroviral therapy for HIV/AIDS in Kenya and Vietnam, and screening for pre-eclampsia in Uganda. In agriculture, their tests help farmers detect aflatoxin contamination in staple crops like maize, a significant food safety issue in regions such as Sub-Saharan Africa. By providing rapid, affordable results at the point-of-care, these diagnostics empower community health workers, improve clinical decision-making, and help prevent the waste of contaminated food supplies, directly impacting public health and economic security.

● Partnerships and funding

Diagnostics For All has cultivated strategic collaborations with a wide array of global health and development organizations to advance its work. Major funders and partners have included the Bill & Melinda Gates Foundation, the United States Agency for International Development, the National Institutes of Health, and the United Kingdom's Department for International Development. It has also worked closely with implementation partners like the Elizabeth Glaser Pediatric AIDS Foundation and research institutions such as Brigham and Women's Hospital for field studies. These partnerships have been crucial for securing grant funding, conducting clinical validations, and navigating the complex regulatory pathways required for diagnostic devices.

● Challenges and future directions

Despite its technological successes, the organization faces significant hurdles common to the global health diagnostics field, including navigating diverse international regulatory landscapes, achieving sustainable manufacturing at scale, and integrating new tools into entrenched health systems. Future directions involve expanding its test menu to address other pressing needs like antimicrobial resistance and nutritional deficiencies, and further miniaturizing and simplifying devices for even broader use. Continued innovation in materials science and partnerships with local manufacturers in regions like Southeast Asia and East Africa are seen as key to achieving long-term, widespread impact and moving beyond pilot programs to systemic adoption.